U2Bio CO. LTD. (XKON:A221800) announced a private placement of series 7 unsecured private convertible debentures for gross proceeds of KRW 7,000,000,000 on April 12, 2019. The transaction will include participation from Corporation Andy S. The bonds will be fully convertible into 50,000 shares at a fixed conversion price of KRW 14,000 from April 18, 2021 to March 18, 2022 and will mature on April 18, 2022. The bonds will carry no coupon rate and yield to maturity of 3%. The payment date of the transaction is April 18, 2019. The transaction was approved by the board of directors of the company.